ClinicalTrials.gg
Active, not recruitingNCT05511792TAILOR-TAVRUpdated Oct 21, 2026

Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)

An interventional study of TAVR for BAV Using Down Sizing with the Evolut Pro platform and TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform in Aortic Stenosis With Bicuspid Valve, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Active, not recruiting at 15 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now Active, not recruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
13th of 47
206 · median 120
Started
2022
with 5 others
No phase
37 of 69
20 open now
Primary completion
2026-06
later than 22 of 50 live
Registered
29th of 69
by date

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 13th largest by planned enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2022, is one of 37 with no phase, reaches primary completion later than 22 of the 50 other live ones, and was the 29th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

To compare down sizing strategy versus annular sizing strategy technique (control group) in Type 0 bicuspid aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR) with self-expanding valves (SEVs): a randomized superiority trial

Read the detailed description

Transcatheter aortic valve replacement (TAVR) has emerged as a favorable alternative for severe symptomatic aortic stenosis (AS) patients of all surgical risk profiles. Patients with bicuspid aortic valve (BAV) underwent TAVR had similar 30-day mortality as well as stroke and new pacemaker implantation rates compared to tricuspid aortic valve (TAV) subjects, but carried higher risk of moderate/severe perivalvular leakage (PVL), conversion to surgery and device failure. Clinical experience in China suggests BAV and heavy calcium burden are more common among TAVR candidates than US/EU cohorts.

Morphological characteristics at supra-annular structure (from annulus to the level of sinotubular junction) are quite complex in BAV, especially concomitant with heavily calcified leaflets. From our previous single center clinical practice, "waist sign" above the annulus during balloon aortic valvuloplasty in TAVR was often observed in patients with bicuspid AS, suggesting that supra-annular structures are the most constrained portion of BAV anatomy where the prosthesis anchors and seals. Therefore, we developed a balloon based supra-annular sizing strategy for self-expanding valves implantation in BAV and the device failure rate as well as pacemaker implantation rates were relatively low as shown in previous cohort study. Several other studies have also achieved successful outcomes associated with device "down sizing" (using a device smaller than that recommended by annular sizing).

The aim of this study is to compare "down sizing"strategy (experimental group) versus annular sizing strategy (control group) in BAV patients undergoing TAVR with self-expanding valves.

03

Conditions studied

  • Aortic Stenosis With Bicuspid Valve
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 65 years;
  2. Age \<65 years and age ≥ 60 years with high surgical risk after combing STS Risk Estimate (≥ 8%), Katz activities of Daily Living, major Organ System Dysfunction and Procedure-Specific Impediment;
  3. Severe, bicuspid aortic stenosis: Mean gradient ≥40 mmHg OR Maximal aortic valve velocity ≥4.0 m/sec OR Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2); if SVi \<35mL/m2, low-dose dobutamine stress echocardiography is required;
  4. classification ≥ II;
  5. Type 0 (Sievers classification) by MDCT;
  6. Perimeter-derived annulus diameter ranges from 20.0 mm to 26.0 mm;
  7. Candidate for Transfemoral TAVR;
  8. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.

Exclusion criteria

Exclusion Criteria:

  1. Any for Self-expanding bioprosthetic aortic valve deployment Leukopenia (WBC \< 3000 cell/mL), acute anemia ( \< 9 g/dL), Thrombocytopenia (Plt\< 50,000 cell/mL).
  2. Active sepsis, including active bacterial endocarditis with or without treatment;
  3. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment [(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].
  4. Stroke or (TIA) within 3 months (90 days) of the procedure.
  5. Estimated \< 12 months (365 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease.
  6. Any Emergent surgery required before TAVR procedure.
  7. A known or contraindication to any of the following that cannot be adequately medicated:aspirin or heparin (HIT/HITTS) and bivalirudin; clopidogrel; Nitinol (titanium or nickel); contrast media
  8. Gastrointestinal (GI) bleeding that would preclude anticoagulation.
  9. Subject refuses a blood transfusion.
  10. Severe dementia (resulting in either inability to provide for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
  11. Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams.
  12. Currently participating in an drug or another device study (excluding registries).
  13. Hypertrophic cardiomyopathy (HCM with myocardium more than 1.5cm without an identifiable cause) with obstruction (HOCM).
  14. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
  15. Severe mitral stenosis amenable to surgical replacement or repair.
  16. Aortic valve type cannot be determined (Sievers classification).
  17. Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe"unfolding" and horizontal aorta(Annular Angulation>70°).
  18. Ascending aorta diameter > 50 mm.
  19. Aortic or iliofemoral vessel characteristics that would preclude safe placement of the introducer sheath.
  20. Patient is considered high risk for TAVR by CT corelab, including coronary obstruction, annular rupture and other severe TAVR-Related complications.
  21. Previous pacemaker implantation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
206 participants (estimated)

Study arms

  • Experimental
    TAVR with down sizing strategy

    Balloon sizing will be used during procedural. Pre-dilation with balloon size just below the annular size. 20mm for annular size of 20-23mm. 23mm for annular size 23-26mm. Waist sign with less than mild contrast regurgitation: Evolut PRO Valve one size smaller than manufacturer recommendation and Target implant depth 0-3mm. No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: Evolut PRO annular sizing (per manufacturer recommendation) with implant depth 0-3mm.

    Procedure: TAVR for BAV Using Down Sizing with the Evolut Pro platform

  • Active comparator
    TAVR with standard sizing strategy

    Pre-dilation with balloon size just below the annular size. 20mm for annular size of 20-23mm. 23mm for annular size 23-26mm. The prosthesis size of Evolut PRO will be chosen based on manufacturer recommendation. The target implant depth will be 0-3mm.

    Procedure: TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform

Interventions

  • ProcedureTAVR for BAV Using Down Sizing with the Evolut Pro platform

    Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves

    Also known as: Down Sizing Strategy

  • ProcedureTAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform

    Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves

    Also known as: Standard Sizing Strategy

06

What researchers measure

Primary outcomes

  1. Composite endpoint of Clinical Event Rate of Device Success (VARC-3), Free of pacemaker implantation, and Free of new onset complete left bundle branch block at 1 month

    Composite endpoint of Device Success (VARC-3), Free of pacemaker implantation, and Free of new onset complete left bundle branch block at 1 month

    Time frame: 1 month after index procedure

Secondary outcomes

  1. New onset complete left bundle branch block

    New onset complete left bundle branch block with QRS ≥120ms at 1 month

    Time frame: 1 month after index procedure

  2. Permanent pacemaker implantation

    Permanent pacemaker implantation within one month

    Time frame: 1 month after index procedure

  3. Device success Rate

    Device success per VARC-3 definition

    Time frame: 1 month after index procedure

  4. More than (≥) moderate regurgitation

    More than (≥) moderate regurgitation on echocardiography at 1month

    Time frame: 1 month after index procedure

07

Study locations

15 sites
08

References and documents

Publications

  • Guo Y, Liu X, Li R, Ng S, Liu Q, Wang L, Hu P, Ren K, Jiang J, Fan J, He Y, Zhu Q, Lin X, Li H, Wang J. Comparison of downsizing strategy (HANGZHOU Solution) and standard annulus sizing strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement: Rationale and design of a randomized clinical trial. Am Heart J. 2024 Aug;274:65-74. doi: 10.1016/j.ahj.2024.04.011. Epub 2024 May 1. PubMed 38701961 ↗

Individual participant data

Plan to share: No — undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jun 2026, 47 months.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 47 months is close to that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Jun 2022 → Jul 2022, primary completion Jul 2026 → Jun 2026 and completion Jun 2030 → May 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Aug 23, 2022
StartActual
Jul 20, 2022was Jun 2022
Primary completionActual
Jun 22, 2026was Jul 2026
CompletionEst.
May 30, 2031was Jun 2030
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 21, 2026
Start date
Jun 27, 2022→Jul 20, 2022
Oct 21, 2026
Primary completion
Jul 30, 2026→Jun 22, 2026 (actual)
Oct 21, 2026
Study completion
Jun 30, 2030→May 30, 2031
Oct 21, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Active, not recruiting
    Start date Jun 27, 2022→Jul 20, 2022
    Primary completion Jul 30, 2026→Jun 22, 2026 (now actual)
    Study completion Jun 30, 2030→May 30, 2031
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 5 other changes: identifiers, verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05511792
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Jul 20, 2022
Primary completion
Jun 22, 2026
Completion
May 30, 2031 (estimated)
Last update
Oct 21, 2026

Study contacts

Jian' an Wang, PhD, MD
study chair · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion